verapamil has been researched along with Diabetic Nephropathies in 21 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 6.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| " We performed a randomized-controlled trial of lisinopril alone (an ACEI) or in combination with verapamil (a CCB) as a therapy for DN in type 2 diabetes mellitus (T2DM) patients with hypertension (HTN) and urinary albumin creatinine ratio (UACR) (30-300 mg/g) also to evaluate their effect on UACR, the angiogenic proteins: Angiopoietin 2 (Ang-2) and Endostatin (EST)." | 5.41 | Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial. ( Abdel-Aleem, E; El-Mesallamy, HO; Salem, M; Sallam, AM, 2021) |
| "The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension." | 5.20 | The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015) |
| " We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks." | 5.13 | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008) |
| "The present randomized, open label, parallel group designed study tests the hypothesis that, at similar levels of blood pressure, the combination of an ACE inhibitor, trandolapril (T) with the non-DHPCA, verapamil (V) produces a greater reduction in proteinuria over either agent alone at one year." | 5.08 | Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. ( Bakris, GL; DeQuattro, V; McMahon, FG; Weir, MR, 1998) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 2.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| "Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy." | 2.71 | The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. ( , 2003) |
| "Microalbuminuria is an early marker of diabetic nephropathy, and its prevention can be considered to be the primary prevention of diabetic nephropathy." | 2.69 | Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. ( Remuzzi, G; Ruggenenti, P, 1998) |
| "Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect." | 2.68 | Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997) |
| "Although end-stage renal disease (ESRD) currently affects only a small percentage (<0." | 2.42 | Calcium channel blockers and the kidney. ( Sica, D, 2004) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Treatment with enalapril reduced the degree of proteinuria at three months (36." | 1.27 | Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. ( Jackson, B; Whitty, MR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Lido, P | 1 |
| Romanello, D | 1 |
| Tesauro, M | 1 |
| Bei, A | 1 |
| Perrone, MA | 1 |
| Palazzetti, D | 1 |
| Noce, A | 1 |
| Di Lullo, L | 1 |
| Calò, L | 1 |
| Cice, G | 1 |
| Salem, M | 1 |
| Sallam, AM | 1 |
| Abdel-Aleem, E | 1 |
| El-Mesallamy, HO | 1 |
| Tabur, S | 1 |
| Oğuz, E | 1 |
| Sabuncu, T | 1 |
| Korkmaz, H | 1 |
| Çelik, H | 1 |
| Albayrak, B | 1 |
| Cankaya, E | 1 |
| Cetinkaya, R | 1 |
| Cerrah, S | 1 |
| Bilen, Y | 1 |
| Toto, RD | 1 |
| Tian, M | 1 |
| Fakouhi, K | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Sica, D | 1 |
| Reams, GP | 1 |
| Bakris, GL | 2 |
| Mangrum, A | 1 |
| Copley, JB | 1 |
| Vicknair, N | 1 |
| Sadler, R | 1 |
| Streier, K | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Weir, MR | 1 |
| DeQuattro, V | 1 |
| McMahon, FG | 1 |
| Guelpa, G | 1 |
| Faller, J | 1 |
| Hess, B | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Jackson, B | 2 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Johnston, CI | 1 |
| Whitty, MR | 1 |
| Bank, N | 1 |
| Lahorra, MA | 1 |
| Aynedjian, HS | 1 |
4 reviews available for verapamil and Diabetic Nephropathies
| Article | Year |
|---|---|
Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?
Topics: Cardio-Renal Syndrome; Diabetes Mellitus; Diabetic Nephropathies; Female; Heart Failure; Humans; Hyp | 2022 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Calcium channel blockers and the kidney.
Topics: Black or African American; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Dilti | 2004 |
Do calcium channel blockers have renal protective effects?
Topics: Aging; Animals; Calcium Channel Blockers; Clinical Trials as Topic; Cyclosporine; Diabetic Nephropat | 1994 |
8 trials available for verapamil and Diabetic Nephropathies
| Article | Year |
|---|---|
Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic | 2021 |
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit | 2015 |
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2008 |
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2003 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; | 1997 |
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabete | 1998 |
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diabetes M | 1998 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
9 other studies available for verapamil and Diabetic Nephropathies
| Article | Year |
|---|---|
The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood | 2016 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
[Obesity in the service of Justice. New drug-combination leads to protection of the kidney].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Diabet | 1997 |
[Diabetic nephropathy with nephrotic syndrome--apropos of 2 cases. Advantages of combined conversion enzyme inhibitor and non-dihydropyridine calcium antagonist treatment].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; | 2000 |
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2002 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; | 1988 |
Acute effect of calcium and insulin on hyperfiltration of early diabetes.
Topics: Animals; Bicarbonates; Blood Pressure; Calcium; Carbon Dioxide; Diabetes Mellitus, Experimental; Dia | 1987 |